C07K2319/035

Multimeric IL-15-based molecules

The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

RECOMBINANT YEAST HOST CELLS EXPRESSING CELL-ASSOCIATED HETEROLOGOUS PROTEINS

The present disclosure concerns recombinant yeast host cells expressing cell-associated heterologous proteins which are expressed during the propagation phase of the recombinant yeast host cells and processes for propagating same. The recombinant yeast host cells can be 5 used to make a yeast composition or a yeast product enriched in the heterologous proteins.

A GENETICALLY MODIFIED LACTOBACILLUS AND USES THEREOF

The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a Lactobacillus sp which colonizes the gastrointestinal tract. The anti-infective activity can be a bacteriocidal or bacteriostatic peptide, an antibody or fragment thereof which specifically recognizes a pathogen, or a phage, or a lytic peptide from a phage which specifically targets a certain pathogen.

ANTIMICROBIAL PROTEIN FOR USE IN THE MEDICAL FIELD

The invention relates to a synthetic fusion protein having high antimicrobial activity. In particular, the invention relates to the use of said protein and compositions that include it in the medical field to combat infections caused by pathogenic microorganisms, in particular gram+bacteria, viruses, mycoplasma and fungi.

ANTIMICROBIAL PROTEIN AND RELATED USE IN AGRICULTURE

The invention relates to a synthetic fusion protein having high antimicrobial activity. In particular, the invention relates to the use of said protein in the agricultural field to combat infections caused by plant pathogenic microorganisms.

COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS

The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.

Claudin-18.2-specific immunoreceptors and T cell epitopes

The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Chimeric polypeptide assembly and methods of making and using the same

The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

Kappa myeloma antigen chimeric antigen receptors and uses thereof

The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.

CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES

The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.